Menu Back to Regulatory-Science-Forum

Overview

DIA has decided to change the format of the upcoming DIA Regulatory Science Forum from "face-to-face" (in-person) to entirely virtual.

This valuable forum WILL continue and be extended on the following dates, 28-30 September, in an entirely virtual meeting format, with both speakers and attendees participating remotely via a digital platform. More details will be provided in the coming weeks.

Read FAQ now


DIA’s mission – to work across the healthcare continuum to ensure patients receive the therapies they need – is more essential than ever during times like these. DIA acknowledges the time and effort that has gone into planning and preparing for the Forum, and trusts that everyone will understand the need to respond to current, evolving health concerns in a responsible manner. These precautions are being taken to ensure the health and safety of our entire, global DIA family.

DIA is committed to exploring all possible avenues to provide a productive setting and a fulfilling meeting experience. We appreciate your patience as we work through technical requirements and any potential challenges.


The Regulatory Science Forum is a platform for sharing knowledge derived from regulatory science research and analyses conducted at the academic, industry and regulatory levels, promoting open dialogue between all stakeholders. The Forum will discuss where more research is needed, as well as the best ways to promote the widespread implementation of findings, recommendations, and other results.

Featured topics

• Why is Regulatory Science research important?
• Regulatory Science Training and Network in European Academia
• Maximizing the Value and Impact of Regulatory Science Research
• HTA-Regulatory Cooperation
• Stakeholder & Patient Engagement
• Body of Evidence
• Complex Clinical Trials
• Pharmacovigilance
• Labelling

Who should attend?

Professionals involved in:

  • Regulatory Science
  • Regulatory Strategy
  • Regulatory Intelligence
  • Scientific Advice
  • Data analysis
  • Policy
  • Patient Engagement

Learning objectives

By attending this meeting, participants will be able to:

• Understand
• Discuss
• Become aware
• Recognize
• Discover

Program Committee

  • Marieke  De Bruin, PharmD, PhD
    Marieke De Bruin, PharmD, PhD Director, Copenhagen Centre for Regulatory Science
    University of Copenhagen, Denmark
  • Sini  Eskola, MPharm, MSc
    Sini Eskola, MPharm, MSc Director Regulatory Affairs
    European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
  • Helga  Gardarsdottir, DrSc
    Helga Gardarsdottir, DrSc Associate Professor in Drug Regulatory Sciences
    Utrecht University, Netherlands
  • Anthony  Humphreys, MPharm
    Anthony Humphreys, MPharm Head of the Regulatory Science and Innovation Task Force
    European Medicines Agency, Netherlands
  • Anne Vinther Morant, PhD, MSc
    Anne Vinther Morant, PhD, MSc Regulatory Science Consultant
    Anne Morant Consulting, Denmark
  • Marjon  Pasmooij, PhD
    Marjon Pasmooij, PhD Science Programme Manager
    Medicines Evaluation Board, Netherlands
  • Sara  Torgal
    Sara Torgal Scientific Programmes Manager
    DIA, Switzerland
  • Aimad  Torqui
    Aimad Torqui Director Global Regulatory Policy
    MSD, the Netherlands, Netherlands
Load More

Contact us

Registration Questions?

Send Email
+41 61 225 51 51

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download